CODA Biotherapeutics
c/o JLABS, 329 Oyster Point Blvd, 3rd Floor
South San Francisco
CA
94080
United States
Website: http://www.codabiotherapeutics.com/
12 articles with CODA Biotherapeutics
-
CODA Biotherapeutics Announces Preclinical Data From Epilepsy Program to be Presented at American Society of Gene & Cell Therapy 25th Annual Meeting
5/5/2022
CODA Biotherapeutics, Inc. today announced that preclinical data from the Company's focal epilepsy program will be featured as a poster presentation at the American Society of Gene & Cell Therapy 25th Annual Meeting being held virtually and in person, May 16-19, 2022, in Washington, D.C.
-
Susan Catalano, Ph.D., joined CODA Biotherapeutics as chief scientific officer after 14 years as CEO of Cognition Therapeutics, the company she founded in 2007 and took public in 2021.
-
CODA Biotherapeutics Names Susan Catalano, Ph.D., as Chief Scientific Officer
3/8/2022
CODA Biotherapeutics, Inc. today announced the appointment of Susan Catalano, Ph.D., as chief scientific officer.
-
A member of BioSpace’s Class of 2021, CODA aims to modify neuronal cell populations using gene therapy to express a tunable ligand-gated ion channel.
-
CODA Biotherapeutics' Chemogenetic Gene Therapy Platform Can Control Focal Seizures in vivo
12/7/2021
CODA Biotherapeutics, Inc. ("CODA"), today announced the presentation of preclinical data suggesting that the Company's chemogenetic gene therapy platform can control focal seizures in vivo.
-
CODA Biotherapeutics Closes $28 Million Financing led by Pacira BioSciences
12/2/2021
CODA Biotherapeutics, Inc. today announced it has closed on $28 million in financing led by Pacira BioSciences, Inc.
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
-
CODA Biotherapeutics Receives Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) to Help Advance its Next-Generation Gene Therapy-Mediated Chemogenetic Platform
11/10/2020
NINDS Small Business Innovation Research grant of $670K over two years to support CODA's neuropathic pain program Company also selected for collaboration with NIH's National Center for Advancing Translational Science
-
CODA Biotherapeutics Announces Research Collaboration With The Facial Pain Research Foundation
5/20/2020
Strategic partnership supports CODA's efforts to develop gene-therapy mediated treatments and cures for trigeminal neuralgia and related neuropathic pain [20-May-2020] SOUTH SAN FRANCISCO, Calif. , May 20, 2020 /PRNewswire/ -- CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform, today annou
-
CODA Biotherapeutics Acquires Attenua and Three Clinical Stage Assets
2/5/2020
CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform, today announced it has completed the acquisition of Attenua, Inc.
-
CODA Biotherapeutics Deepens Gene Therapy Expertise with Industry Veteran, Annahita Keravala, Ph.D., and Key Promotions
11/21/2019
Expansion and development of leadership team drives the company's chemogenetic gene therapy platform toward the clinic in initial core therapeutic areas of chronic neuropathic pain and focal epilepsy
-
CODA Biotherapeutics Announces Series A Extension, Bringing Total Round to $34 Million
11/5/2019
Proceeds will advance company's chemogenetic gene therapy platform toward the clinic with an initial focus on chronic neuropathic pain and focal epilepsy